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Research Enterprise
and individual health standards. It funds
health and medical research through a
highly competitive grant system, and in
2005 awarded gr nts amounting to $412
million.
The past decade has seen increased pres-







Objective:  To report on strategies for, and outcomes of, evaluation of knowledge 
(publications), health and wealth (commercial) gains from medical research funded by 
the Australian Government through the National Health and Medical Research Council 
RC).
gn and methods:  End-of-grant reports submitted by researchers within 6 months 
mpletion of NHMRC funded project grants which terminated in 2003 were used to 
re self-reported publication number, health and wealth gains. Self-reported gains 
 also examined in retrospective surveys of grants completed in 1992 and 1997 and 
ds primarily supporting people (“people awards”) held between 1992 and 2002.
Results:  The response rate for the 1992 sample was too low for meaningful analysis. 
The mean number of publications per grant in the basic biomedical, clinical and health 
services research areas was very similar in 1997 and 2003. The publication output for 
population health was somewhat higher in the 2003 than in the 1997 analysis. For grants 
completed in 1997, 24% (31/131) affected clinical practice; 14% (18/131) public health 
practice; 9% (12/131) health policy; and 41% (54/131) had commercial potential with 
20% (26/131) resulting in patents. Most respondents (89%) agreed that NHMRC people 
awards improved their career prospects. Interpretation is limited by the relatively low 
response rates (50% or less).
Conclusions:  A mechanism has been developed for ongoing assessment of NHMRC 
funded research. This process will improve accountability to the community and to 
government, and refine current funding mechanisms to most efficiently deliver health 
MJA 2006; 184: 282–286
and economic returns for Australia.he
Re
traT  National Health and Medicalsearch Council (NHMRC) is Aus-lia’s leading agency responsible for
the development and maintenance of public
including for research funding.1-4 Australian
medical research is highly innovative and
translated into medically useful treat-
ments.5-8 However, funders of health and
medical research expect quantitative evi-
dence of research impact. Additional fund-
ing for the NHMRC will need to be
supported by evidence of health and wealth
(commercial) gains from the increased fund-
ing delivered following the Health and Med-
ical Research Strategic (Wills) Review in
2000.9 In particular, the NHMRC will be
required to report against Australia’s
National Research Priorities10 and National
Health Priorities11 (Box 1). Recognising this
challenge, the NHMRC established an Eval-
uation and Outcomes Working Committee
in 2003.
The NHMRC has previously commis-
sioned bibliometric analyses of Australia’s
health and medical research publication
output.12-14 Published articles indicate
knowledge gain, but are not a complete
measure of value.15 The task of the Evalua-
tions and Outcomes Working Committee is
to evaluate health and wealth gains derived
from knowledge gained through NHMRC
funding. A key strategy was to enhance the
content, compliance rate for completion,
and evaluation of end-of-grant reports (Box 2).
The new grant reports18 allow better moni-
toring of compliance, and provide an input
to strategic evaluation. They are designed to
provide summary statistics of grant out-
comes. In addition, database management
procedures were strengthened to enable easy
retrieval of information. Another strategy
was the retrospective follow-up of the out-
comes of grants completed in 1992 and
1997 and awards primarily supporting peo-JA • Volume 184 Number 6 • 20 March 2006
R ESEARCH  ENTERPRISEple held between 1992 and 2002 (Box 2).
We report the collective outcome of these
evaluations.
METHODS
Project grants completed in 2003
Investigators holding NHMRC project
grants that were completed in 2003 were
required to submit a report by June 2004.16
Grants completed in 1992 and 1997
A contracted web-based survey of NHMRC
project grants which terminated in 1992 and
1997 was completed in June 2005.16 A sim-
plified version of the new end-of-grant report
was used as the survey instrument. Primary
investigators were contacted by email and in
some instances by telephone and invited to
complete the survey. Current email addresses
were sourced from the NHMRC; however,
these were unavailable for 35% of the 1992
sample and 26% of the 1997 sample.
People awards completed between 
1992 and 2002
The NHMRC funds individuals, including
PhD scholars, postdoctoral fellows, early
career researchers and senior fellows. These
awards are collectively called “people
awards”. A contracted survey of NHMRC
workforce outcomes from people awards
funded between 1992 and 2002 was com-
pleted in June 2005, and was conducted
using a computer-assisted telephone inter-
view system.19 In addition to assessing
knowledge, health and wealth gains, the
survey tracked career paths, benefits of the
scheme with regard to collaborations, net-
working and opportunities, and deficiencies
in the system, including barriers and gaps.
Outcome measures
For all evaluations, the main output indica-
tor for knowledge gain was the number of
publications. No attempt was made to assess
publication quality or impact, which has
been done more comprehensively using
other methods.12-14
The main evaluations reported are for
health and wealth gains. Health gain was
defined as any research with a self-reported
effect on clinical practice or other health
service delivery practice or outcomes,
changes in public health practice, or
changes in health policy. Wealth gain was
defined as any research with self-reported
commercial activity, including commercial
potential and patents.
RESULTS
One hundred and thirty-one reports of
grants completed in 2003 (29% of 454
expected reports) were returned and
reviewed by a panel of 18 experts.
For the surveys of grants completed in
1992 and 1997, the response rate was 44%
of the contactable sample in 1992 (61/139),
and 51% (131/259) in 1997.
Of the eligible population of 1897 recipi-
ents of people awards, 596 (31%) com-
pleted the survey.
Knowledge gain
Grants completed in 2003
In 2003, 56% (73/131) of grants reviewed
focused on National Health Priority Areas.
Cancer accounted for 23% (30/131) of all
grants; cardiovascular disease, 11% (14/131);
mental health, 11% (15/131); diabetes 6%
(8/131); asthma, 3% (4/131); and arthritis
and musculoskeletal conditions, 2% (2/131)
(some research grants addressed more than
one national health priority area).
The publication output per grant in spe-
cific disciplines is shown in Box 3, along
with the average grant expenditure per pub-
lication. However, this latter figure does not
reflect total expenditure per publication, as
the amount contributed by other funding
sources, including those supporting the sal-
aries of senior investigators, is unknown.
Training of postgraduate students is also
an indicator of knowledge gain. In 2003, a
mean of 1.5 candidates (range, 0–6) per
grant progressed or completed their post-
graduate training. For basic biomedical
sciences, the mean was 2 (range, 0–6) per
grant; for clinical medicine, 1.2 (range, 0–4)
per grant; and for public health and health
services research, 1.4 (range, 0–4) per
grant.
Grants completed in 1997
Given the greater eligible sample (259 in
1997 compared with 139 in 1992) and the
higher response rate (51% in 1997, 44% in
1992), we focus predominantly on 1997.
However, trends were similar for both the
1992 and 1997 analysis.16
In 1997, 68% (89/131) of all grants sur-
veyed focused on one or more of the
national research priority areas. There were
206 reports of alignment with national
research priorities among these 89 grants.
Most focused on one or more aspects of
promoting and maintaining good health
(125/206, 61%). Of these 125, 45 targeted
ageing well, ageing productively; 45 preven-
tive health care; 28 a healthy start to life;
1 Priority areas
National Research Priority Areas10
• An environmentally sustainable Australia
• Promoting and maintaining good health
¾ A healthy start to life
¾ Ageing well, ageing productively
¾ Preventative healthcare
¾ Strengthening Australia’s social and 
economic fabric
• Frontier technologies for building and 
transforming Australian industries
• Safeguarding Australia





• Injury prevention and control
• Mental health
• Arthritis and musculoskeletal conditions ◆
2 NHMRC evaluations and outcomes strategy
Outcome Evaluation mechanism Evaluation time frame
Short-term (1 year) New end-of-grant reports
Publications Projects Annually from 2005
Health gain Programs Annually from 2006
Commercial gain Fellowships Annually from 2006
Strategic initiatives Annually from 2006
Medium-term (7–12 years) Retrospective outcomes surveys 
Publications
Health gain
Grants completed  in 1992 and 199716 2005
Commercial gain
Career development 
People awards completed 1992–2002 
(qualitative)17 
2005
All assessments are self-reported outcomes from either end-of-grant reports (short-term) or from retrospective 
outcome surveys (medium-term). ◆MJA • Volume 184 Number 6 • 20 March 2006 283
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economic fabric.
In 1997, 57% of grants (75/131) focused
on one or more national health priorities.
There were 101 reports of alignment with
national health priorities among these 75
grants. Of all grants, 23% (30/131) focused
on cancer; followed by cardiovascular
disease, 16% (21/131); mental health
13% (17/131); and arthritis and musculo-
skeletal conditions, 11% (15/131).
The publication number per grant in the
basic biomedical sciences, the clinical sci-
ences and health services research was very
similar in 1997 and 2003 (Box 3).
In 1997, a mean of 1.3 (range, 0–10)
candidates per grant progressed or com-
pleted their postgraduate training. This is
similar to the results for 2003. For basic
biomedical sciences, the mean was 1.5
(range, 0–10) per grant; for clinical medi-
cine, 1 (range, 0–4) per grant; and for public
health and health services research, 0.7
(range, 0–3) per grant.
Health gain (retrospective analyses)
Effect on practice was assessed primarily by
principal investigator self-report (Box 4).
Examples of clinical or policy effects arising
from their  grant as del ineated by
investigators16 included incorporation of
outcomes of clinical trials into practice.
According to one chief investigator, “the use
of antibiotics and particularly beta-lactam
antibiotics was reduced in the community
studied”. Another reported practice benefit
was increased awareness of the importance
of rotavirus infection causing hospitalisation
of young children.
Health policy outcomes included a more
rigorous basis for falls prevention programs
(particularly influencing policy in New
South Wales and Western Australia).
Public health effects from grants com-
pleted in 1992 included reduction in infant
mortality and change in advice to parents
about the safe sleeping position of infants
from the finding that a prone sleeping posi-
tion increased the risk of sudden infant
death syndrome (SIDS).
Research completed in 1992 also led to
changes to the design and implementation
of control programs worldwide against the
hydatid tapeworm.
Wealth gain (1997 retrospective 
analysis)
In 1997, 41% (54/131) of grants were self-
reported as having commercial potential. Of
all grants, 20% (26/131) resulted in one or
more patents (Box 4): 33% were pending,
50% had been granted, and 17% had
lapsed.
Patents covered diverse areas such as new
diagnostics for liver disease, new methods to
prevent and treat inflammatory skin disor-
ders, and new cancer therapeutics. There
were also multiple patents around vaccine
technology, including vaccines aimed at pre-
venting multiple diseases.
People awards
Ninety-eight per cent (577/589) of respond-
ents indicated that their NHMRC award
developed expertise which was relevant or
highly relevant to Australia’s medical
research and development needs, and 95%
(560/589) indicated that the expertise was
relevant to international needs. Further-
more, 89% (524/589) of respondents indi-
cated that their NHMRC award improved
their career prospects.
On the negative side, 81% (478/587)
agreed that lack of continuing employment
is a barrier to effective medical research, and
72% (423/587) believed that career paths in
medical research are poorly defined. Eighty
per cent (470/585) disagreed that the Aus-
tralian health and medical research environ-
ment provides a secure and long-term career
path. Funding was considered to be the
major impediment to the development of
research by 61% (362/594) of those sur-
veyed.
DISCUSSION
The bibliometric analyses reported
previously12-14 and the preliminary NHMRC
grant outcome evaluations reported here
indicate that NHMRC grants make a signifi-
cant contribution to knowledge creation
through scientific publication. Importantly,
knowledge from a substantial number of
grants over a 7–12-year time frame is trans-
lated to outcomes that affect Australia’s
health and economic wellbeing. However, it
is important to consider the potential for
sample bias, given the relatively low
response rates in our preliminary assess-
ments. In the future, it will also be impor-
tant to determine methods to quantify the
economic benefit of changes in practice and
policy (in terms, for example, of both
changed health care costs and improved
patient outcomes leading to human produc-
tivity). Likewise, it will be important to
capture evidence of the economic effect
arising from commercialisation and patent-
ing activity.5
Comparison of results from the 1997 and
2003 analyses is of interest. However, there
are two major confounding variables. First,
the size of grants and the cost of research
both increased from 1997 to 2003. Second,
the time frame for assessment in the two sets
4 Health and commercial gains — 
retrospective analysis of NHMRC 
grants completed in 1997 16
Number %
Health gain
Clinical practice 31/131 24%
Public health practice 18/131 14%
Health policy 12/131 9%
Commercial gain 
Number of grants with 




Patent Cooperation Treaty 6/31 19%
Australian 3/31 10%
International 17/31 55%














Basic biomedical 7.0 (0–25) 37 100 7.5 (0–54) 63 000
Clinical medicine 
and science
5.2 (0–14) 47 600 4.5 (0–20) 61 000
Population health 4.6 (1–10) 34 500 6.4 (1–16) 45 300
Health services 3.0 (1–3) 22 800 4.3 (2–10) 37 400
* Average expenditure per grant = total $ value of grant/number of publications. Both analyses were 
conducted in 2005. ◆284 MJA • Volume 184 Number 6 • 20 March 2006
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tion for the 2003 sample, and 7 years after
completion for the 1997 sample. However,
it is likely that a 7-year retrospective analysis
of the 2003 grants would reveal further
publications, and that grant expenditure per
publication would be largely similar to that
for the 1997 analysis. The publication out-
put for population health was higher in the
2003 compared with the 1997 analysis. This
may be due to greater recent investment in
this area, reflected by the increase in the
average grant expenditure per publication in
2003 compared with 1997.
Although Australian medical research has
been translated into medically useful treat-
ments,5-7 most development of Australian
medical research was not performed in Aus-
tralia.8,9 Australian ideas and publications
were over-represented in the US patent liter-
ature on patent applications filed by non-
Australian entities.9 If Australia is to contrib-
ute significantly to international health
advances, a larger fraction of innovation
must be developed in Australia. The level of
engagement with the commercialisation
process in the 1997 analysis is a gratifying
outcome given that this is often the first step
in developing a product which may contrib-
ute to health gain. The local protection of
intellectual property allows inventors to
interact with Australian biotechnology or
small innovative companies and/or larger
multinationals in a way that should bring
substantial economic returns. It will be
important to track the future development
and commercialisation of patents reported
in the current cohort of grants.
There was an overwhelmingly positive
assessment of NHMRC people awards in
contributing to the development of know-
ledge and skills.19 In addition, the high
reputation and competitive standard of
these awards was considered very important
in improving future career prospects. On the
negative side, there was insecurity about
career pathways and employment prospects
which was perceived to inhibit research
development. This probably relates to the
highly competitive and fixed term nature of
people awards, both of which reflect the
limited funding available.
Our first attempt to evaluate outcomes
beyond publications is also useful for refining
the mechanism of data capture. Measures are
currently being implemented to improve the
rate of end-of-grant report return, which
exceeded 80% for 2005. Although the retro-
spective analyses collected data from grants
completed in 1992 and 1997, it was only
possible to obtain an adequate sample size
from grants completed 7 years before the
survey (1997 sample). Such retrospective
analysis is important, as not all manuscripts
arising from a grant are accepted for publica-
tion at the time a final report is due. Similarly,
not all higher degree students will have com-
pleted their candidature. The health and
wealth outcomes of grants are also unlikely to
have developed significantly 6 months after
completion of funding. However, future
potential is certainly identifiable. Linkage
between funding and outcomes over longer
periods may be better tracked in the reverse
direction from measurable outcomes to their
funding sources.17 However, this approach
may not be appropriate, given the increased
variety of funding contributions that under-
pin research.
We suggest that a 5–7-year reporting time
frame allows a sufficient period for health
and wealth outcomes to have appeared,
while minimising loss to follow-up. The
magnitude and effect of research translation
is still difficult to quantify, given both prob-
lems with outcome data collection and the
time lag between grant completion and
research translation. The end-of-grant report
and the retrospective survey instrument will
be further refined on the basis of this initial
experience.
Communication of outcomes of research
funded by the NHMRC to the Australian
community is an important aspect of medi-
cal research accountability. In the 2003 anal-
ysis, a panel of experts identified 10 grants
for showcasing as case-studies in a booklet
highlighting research outcomes to the com-
munity (“Ten of the Best”,20 Box 5). This
type of community reporting will probably
be expanded as the NHMRC moves to an
outcome-based approach to research report-
ing. Strategic groupings, organised accord-
ing to major disease, population and
discipline groups, will be responsible for
identifying the strengths and gaps and for
recommending strategies to ensure that
there is appropriate capacity (people, funds
or facilities) to best meet future challenges.
As the evaluation process is expanded, it
will be possible to relate outcomes back to
specific funding schemes so that the most
effective and efficient funding mechanisms
can be identified.21 Outcome analyses can
then be used to inform future funding strat-
egies. As well as identifying Australian
research strengths, outcome evaluation will
highlight areas of weakness that require
specific investment and capacity-building.
In conclusion, outcome analyses and attri-
bution to the initial funding source presents a
significant challenge to all research funding
agencies. There is no single established
method that provides valid assessment of the
specific outcomes of a single grant. In the last
triennium (2003–2005), the NHMRC has
laid the foundation for a number of different
evaluation methodologies. However, further
significant work is required to refine data-
bases and outcome analyses. The goal will be
to establish the highest standards of account-
ability and community dialogue, and to
refine current funding mechanisms to most
efficiently deliver health and economic
returns for Australia.
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